A Phase I Study of GTI-2040 in Combination With Oxaliplatin and Capecitabine in Patients With Advanced Metastatic Solid Tumors

Trial Profile

A Phase I Study of GTI-2040 in Combination With Oxaliplatin and Capecitabine in Patients With Advanced Metastatic Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2016

At a glance

  • Drugs LOR 2040 (Primary) ; Capecitabine; Oxaliplatin
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Apr 2009 Status changed from active, no longer recruiting to completed, according to a Lorus Therapeutics media release.
    • 15 Apr 2009 Results have been reported in Cancer Chemotherapy Pharmacology, according to a Lorus Therapeutics media release.
    • 05 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top